[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584696":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":53,"collaborators":55,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Northwestern University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dupilumab Treatment",null,"Patients who had prior endoscopic sinus surgery for CRSwNP with persistent smell loss initiating dupilumab",[13],"Drug: Dupilumab - Standard Dose",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Dupilumab - Standard Dose","24 weeks of dupilumab 300mg q2 weeks",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Clinical Coordinator","CONTACT","312 6958182","aditi.agarwal@northwestern.edu",{"name":27,"role":23,"phone":24,"phoneExt":10,"email":28},"Bruce Tan, MD","btan@nm.org",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Northwestern University Feinberg School of Medicine","RECRUITING","Chicago","Illinois","60611","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-87.65005,41.85003,{"lat":42,"lon":41},[45,48,50],{"name":46,"role":23,"phone":47,"phoneExt":10,"email":25},"Aditi Agarwal, MBBS, MSCI","312-695-8182",{"name":49,"role":23,"phone":24,"phoneExt":10,"email":28},"Bruce Tan, MD MS",{"name":51,"role":52,"phone":10,"phoneExt":10,"email":10},"Bruce Tan, MD, MS","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[56],{"name":57,"class":58},"Sanofi","INDUSTRY","100584696","olfactory-cleft-obstruction-and-electrophysiological-field-potentials-predict-olfactory-restoration-by-dupilumab-in-crswnp-patients-100584696",false,"NCT06892704","Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.","Olfactory Cleft Obstruction and Electrophysiological Olfactory Bulb Generated Beta Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.","* Well documented history of CRSwNP\n* BSIT age\u002Fsex classified as \"abnormal\" score\n* Self-reported stable olfactory deficit of moderate to severe quality \\> 3 months\n* Prior endoscopic sinus surgery \\>3 months, \\\u003C10 years prior","ALL","18 Years","65 Years",{"count":70,"type":71},30,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are:\n\n1. Does obstruction of the olfactory cleft predict return of the sense of smell?\n2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell?\n\nParticipants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.",[75,76],"Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","Smell Loss",[78,79,76,80],"Dupilumab","Chronic Rhinosinusitis with Nasal Polyps","Electrophysiology","2025-05-12",{"date":83,"type":84},"2025-05-14","ACTUAL",{"date":86,"type":84},"2025-05-01",{"date":88,"type":71},"2027-12-31",{"name":5,"class":6},1]